LEGN (Legend Biotech) Stock Analysis - SEC Filings

Legend Biotech (LEGN) is a publicly traded Healthcare sector company. As of May 21, 2026, LEGN trades at $27.67 with a market cap of $5.01B and a P/E ratio of 0.00. LEGN moved +4.36% today. Year to date, LEGN is +38.45%; over the trailing twelve months it is -6.48%. Its 52-week range spans $16.24 to $51.77. Analyst consensus is strong buy with an average price target of $55.90. Rallies surfaces LEGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find LEGN SEC filings?

Rallies organizes LEGN SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

LEGN Key Metrics

Key financial metrics for LEGN
MetricValue
Price$27.67
Market Cap$5.01B
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$51.77
52-Week Low$16.24
Volume794
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Latest LEGN News

Recent LEGN Insider Trades

  • Huang Ying sold 9.94K (~$87.14K) on Mar 25, 2026.

LEGN Analyst Consensus

11 analysts cover LEGN: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $55.90.

Common questions about LEGN

Where can I find LEGN SEC filings?
Rallies organizes LEGN SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show LEGN 10-K and 10-Q filings?
Rallies organizes LEGN SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is LEGN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LEGN. It does not provide personalized investment advice.
LEGN

Legend Biotech